Agilent has announced ion-exchange and size-exclusion columns designed for the analysis of bio-molecules.
These include monoclonal antibodies, recombinant proteins, peptides, vaccine products and DNA/RNA.
The columns provide robust, reproducible and high-resolution solutions for biopharmaceutical manufacturers to effectively monitor the safety, efficacy and stability of their products.
'With the addition of these new bio-columns, we can now offer our customers significant improvements in charge-based and size-based analytical separations of bio-molecules,' said Helen Stimson, vice president and general manager of Agilent's Consumables and Supplies Division.
'The new columns greatly expand our current bio-columns portfolio, which also include reverse phase columns for intact protein separations and peptide mapping,' she added.
Each new column is individually tested with protein samples to ensure column-to-column and batch-to-batch reproducibility.
The four column ranges and their benefits include: andomicron Agilent Bio SEC-3 size-exclusion columns, a robust 3um particle that offers higher resolution and faster separation times, specifically for the analysis of monoclonal antibody aggregates; andomicron Agilent Bio SEC-5 size-exclusion columns, packed with 5um particles coated with a neutral, hydrophilic coating, making the particle extremely stable under harsh buffer conditions; andomicron Agilent Bio MAb columns, featuring a weak cation exchange (WCX) resin specifically designed for high-resolution separations of monoclonal antibody charge variants; and andomicron Agilent Bio IEX columns, designed for high-resolution, high-recovery and highly efficient separations of proteins, peptides, oligonucleotides and other bio-molecules.
